Adagio Medical Holdings, Inc. 8-K

What Happened
Adagio Medical Holdings, Inc. filed an 8-K on June 12, 2026 reporting that Nasdaq’s Listing Qualifications Department notified the company that its common stock is out of compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price was below $1.00 per share for the prior 30 consecutive business days. The notice does not remove the company’s listing; Adagio has a 180-calendar-day cure period ending December 9, 2026, to regain compliance.

Key Details

• Notice date: June 12, 2026; noncompliance is for falling below the $1.00 minimum bid price under Nasdaq Rule 5550(a)(2).
• Cure period: 180 calendar days (until December 9, 2026) during which the stock will continue to trade on Nasdaq.
• How to regain compliance: a closing bid at or above $1.00 per share for at least ten consecutive trading days triggers compliance certification.
• If needed, a second 180-day period may be available if Adagio notifies Nasdaq it will regain compliance (potentially via a reverse stock split) and meets other listing standards except the bid price.

Why It Matters
This notice signals a potential listing risk: if Adagio fails to meet the $1.00 minimum bid requirement within the cure periods, Nasdaq could begin delisting proceedings. For investors, the immediate impact is limited—shares continue to trade on Nasdaq—but there is increased risk of delisting or corporate actions (such as a reverse stock split) that could affect share count and price. The company said it is considering options to regain compliance but provided no assurance it will succeed.